Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 5, 2012, Pages 493-503

  Inderjeeth, Charles A ^a   Chan, Kien ^b   Kwan, Kevin ^b   Lai, Michelle ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Efficacy; Fracture reduction; Osteoporosis treatment; Time to onset

Indexed keywords

ALENDRONIC ACID; CALCITONIN; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ALZHEIMER DISEASE; ANY CLINICAL FRACTURE; BONE DENSITY; CLINICAL VERTEBRAL FRACTURE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FRACTURE REDUCTION; HIP FRACTURE; HUMAN; LOW DRUG DOSE; MORPHOMETRIC VERTEBRAL FRACTURE; MORPHOMETRICS; NONVERTEBRAL FRACTURE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SPINE FRACTURE; SYSTEMATIC REVIEW;

BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 84868193399     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0349-1     Document Type: Review

References (51)

1. World Health Organisation (2004) WHO Technical report series, no. 921
2. Economics Access (2001) The burden of brittle bones: costing osteoporosis in Australia. Access Economics Pty Ltd, Canberra
3. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S-17S (discussion 17S-19S)
4. Eisman J, Clapham S, Kehoe L (2004) Australian BoneCare Study. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969-1975
5. Chilov MN, Cameron ID, March LM (2003) Australian National Health and Medical Research Council. Evidence-based guidelines for fixing broken hips: an update. Med J Aust 179:489-493
6. Nguyen TV, Center JR, Eisman JA (2004) Osteoporosis: underrated, under diagnosed and undertreated. Med J Aust 180:S18-S22
7. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
8. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026
9. Brooks PM, Hooper MJ, Smallwood RA (2004) Bone and joint disease: prevention and control. Med J Aust 180:S4-S5
10. Philips P, Braddon J (2004) Osteoporosis - diagnosis, treatment and management. Aust Fam Physician 33:111-119
11. Seeman E, Eisman JA (2004) Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk factor. Med J Aust 180:298-303
12. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
13. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
14. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
15. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention Trial. J Am Geriatr Soc 50:409-415
16. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Interventional Trial. J Clin Endocrinol Metab 85:4118-4124
17. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9:461-468
18. Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ et al (2000) Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 85:1783-1788
19. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD et al (2006) Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS - international. Clin Drug Invest 26:63-74
20. Chestnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
21. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC et al (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone (NY) 37:651-654
22. Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Oncemonthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207-213
23. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH et al (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754
24. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
25. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M et al (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140-1143
26. Qu Y, Wong M, Thiebaud D, Stock JL (2005) The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 21:1955-1959
27. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (NY) 33:522-532
28. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. JAMA 282:1344-1352
29. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
30. Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427-431
31. Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J (2003) Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 14:437-441
32. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549
33. Boonen S, McClung MR, Eastell R, El-Haji Fuleihan G, Barton IP et al (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52:1832-1839
34. Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP et al (2005) Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 17:150-156
35. Roux C, Seeman E, Eastell R, Adachi J, Jackson RD et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433-439
36. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
37. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129-135
38. Sato Y, Kanoko T, Satoh K, Iwamoto J (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease. Arch Intern Med 165:1737-1742
39. Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142-151
40. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25-34
41. Masud T, McClung M, Geusens P (2009) Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 4:445-449
42. Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743-1748
43. Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 64:811-816
44. Sato Y, Honda Y, Iwamoto J (2007) Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 68:911-915
45. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
46. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822
47. Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J et al (2006) Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21:1113-1120
48. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
49. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
50. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292-299
51. Sontag A, Krege JH (2010) First fractures among postmenopausal women with osteoporosis. J Bone Miner Metab 28:485-488